Uveal Melanoma - Comparative Study
Conditions: Uveal Melanoma Interventions: Diagnostic Test: Sonography, color fundus photography Sponsors: Medical University of Vienna Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Conditions: Melanoma Stage III; Melanoma Stage IV Interventions: Drug: L19IL2; Drug: L19TNF; Drug: L19IL2/L19TNF; Drug: KEYTRUDA ® Sponsors: Philogen S.p.A.; Merck Sharp& Dohme LLC Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Conditions: Neoplasms; Non-small-cell Lung Cancer; Melanoma; Squamous Cell Carcinoma of the Head and Neck; Renal Cell Carcinoma; Urothelial Carcinoma; Colorectal Carcinoma; Ovarian Carcinoma Interventions: Drug: PF-07820435; Biological: Sasanlimab Sponsors: Pfizer Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Impact of Anti PD-1 Therapy in Children, Adolescents and Young Adults (CAYA) Melanoma Patients
Conditions: Early Melanoma; Advanced Melanoma Sponsors: Azienda Ospedaliera di Perugia Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma
Conditions: Uveal Melanoma Interventions: Diagnostic Test: Clinical examination and multimodal ocular imaging Sponsors: Medical University of Vienna Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
YASU Research Registry: For Young Adults With Cancer
Conditions: Cancer; Leukemia; Sarcoma; Germ Cell Cancer; Lymphoma; Colorectal Cancer; Melanoma; Breast Cancer Sponsors: Young Adult Survivors United; Staunton Farm Foundation; Elsie H. Hillman Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
BostonGene and Exigent Genomic INsight Study
Conditions: Breast Cancer; Non-small Cell Lung Cancer; Melanoma; Sarcoma Sponsors: BostonGene; Exigent Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
Conditions: Solid Tumor, Adult; Colorectal Cancer; Pancreatic Cancer; Malignant Melanoma; Ras (Kras or Nras) Gene Mutation; BRAF Gene Mutation; CRAF Gene Mutation; Non-Small Cell Lung Carcinoma; Thyroid Carcinoma; Gliomas, Malignant Interventions: Drug: IK-595 Sponsors: Ikena Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2024 Category: Research Source Type: clinical trials
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Conditions: Advanced Esophageal Squamous Cell Carcinoma; Advanced Renal Cell Carcinoma; Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8; Esophageal Carcinoma; Gastroesophageal Junction Adenocarcinoma; Hepatocellular Carcinoma; Locally Advanced Urothelial Carcinoma; Lung Non-Small Cell Carcinoma; Malignan...
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Conditions: Head and Neck Cancer; Malignant Melanoma; Colorectal Cancer; Renal Cell Carcinoma; Cervical Cancer; Breast Cancer Interventions: Drug: GM103 (Part A); Drug: GM103 (Part B); Drug: GM103 and Pembrolizumab (Part C) Sponsors: GeneMedicine Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 19, 2024 Category: Research Source Type: clinical trials
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
Conditions: Advanced Melanoma Interventions: Biological: Vusolimogene Oderparepvec; Biological: Nivolumab; Biological: Nivolumab + Relatlimab; Biological: Pembrolizumab; Drug: Single-agent chemotherapy Sponsors: Replimune Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2024 Category: Research Source Type: clinical trials
Randomized Clinical Trial of Telenursing for Monitoring Supportive Care Needs in Patients With Lung Cancer and Melanoma Candidates for the First Prescription of Targeted Therapies
Conditions: Lung Neoplasm; Melanoma Interventions: Other: Telenursing interventions for monitoring Supportive Care Needs Sponsors: Regina Elena Cancer Institute Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App
Conditions: Melanoma (Skin); Skin Cancer Interventions: Other: Daily updated ranking on leaderboard; Other: Daily motivational message Sponsors: Herlev Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
Conditions: ICB-refractory Melanoma Interventions: Other: Prebiotic Food-Enriched Diet; Drug: Ipilimumab; Drug: Nivolumab Sponsors: M.D. Anderson Cancer Center Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Patients With BRAF-Positive Metastatic Melanoma
Conditions: BRAF-positive Metastatic Melanoma Sponsors: Novartis Pharmaceuticals Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
